Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is poised for success with their promising pipeline products, including EVO756 and EVO301, and a current valuation of $42 per share which is largely driven by the potential success of EVO756. The potential for the drug to be used in multiple conditions, such as migraine, greatly increases its revenue potential and the success of EVO301 in its Phase 2b study offers further promise for the company's future financial performance.

Bears say

Evommune is a clinical-stage biotechnology company with a focus on developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline products, EVO756 and EVO301, show promise in targeting the MRGPRX2 pathway, and initial clinical data suggest target engagement and potential efficacy in these diseases. However, the company faces risks such as competition from established drugs and the possibility of unexpected safety issues. Additionally, the company's financials are heavily reliant on the success of its clinical programs, which could lead to downside risk if they do not meet expectations.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.